San Raffaele Telethon Institute for Gene Therapy (SR-Tiget)
Ivan Merelli has not added Biography.
If you are Ivan Merelli and would like to personalize this page please email our Author Liaison for assistance.
High parathyroid hormone concentration in tenofovir-treated patients are due to inhibition of calcium-sensing receptor activity.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie Jan, 2018 | Pubmed ID: 29136775
Precise Gene Editing Preserves Hematopoietic Stem Cell Function following Transient p53-Mediated DNA Damage Response.
Cell stem cell Apr, 2019 | Pubmed ID: 30905619
γ-TRIS: a graph-algorithm for comprehensive identification of vector genomic insertion sites.
Bioinformatics (Oxford, England) Mar, 2020 | Pubmed ID: 31589304
Expanded circulating hematopoietic stem/progenitor cells as novel cell source for the treatment of TCIRG1 osteopetrosis.
Haematologica Jan, 2021 | Pubmed ID: 31949009
Hematopoietic stem cell function in β-thalassemia is impaired and is rescued by targeting the bone marrow niche.
Blood Jul, 2020 | Pubmed ID: 32344432
Efficient gene editing of human long-term hematopoietic stem cells validated by clonal tracking.
Nature biotechnology Nov, 2020 | Pubmed ID: 32601433
Modeling, optimization, and comparable efficacy of T cell and hematopoietic stem cell gene editing for treating hyper-IgM syndrome.
EMBO molecular medicine Mar, 2021 | Pubmed ID: 33475257
BAR-Seq clonal tracking of gene-edited cells.
Nature protocols Jun, 2021 | Pubmed ID: 34031609
Oncogene-induced maladaptive activation of trained immunity in the pathogenesis and treatment of Erdheim-Chester disease.
Blood Oct, 2021 | Pubmed ID: 34077954
Premature Senescence and Increased Oxidative Stress in the Thymus of Down Syndrome Patients.
Frontiers in immunology , 2021 | Pubmed ID: 34140950
Oncogene-induced senescence in hematopoietic progenitors features myeloid restricted hematopoiesis, chronic inflammation and histiocytosis.
Nature communications Jul, 2021 | Pubmed ID: 34315896
Myeloid cell-based delivery of IFN-γ reprograms the leukemia microenvironment and induces anti-tumoral immune responses.
EMBO molecular medicine Oct, 2021 | Pubmed ID: 34459560
Integrated Multiomic Profiling Identifies the Epigenetic Regulator PRC2 as a Therapeutic Target to Counteract Leukemia Immune Escape and Relapse.
Cancer discovery Jun, 2022 | Pubmed ID: 35255120
Identification of a retinoic acid-dependent haemogenic endothelial progenitor from human pluripotent stem cells.
Nature cell biology May, 2022 | Pubmed ID: 35484246
Follicular helper T cell signature of replicative exhaustion, apoptosis, and senescence in common variable immunodeficiency.
European journal of immunology Jul, 2022 | Pubmed ID: 35562849
Targeted inducible delivery of immunoactivating cytokines reprograms glioblastoma microenvironment and inhibits growth in mouse models.
Science translational medicine Jul, 2022 | Pubmed ID: 35857642
Mesenchymal stromal cells improve the transplantation outcome of CRISPR-Cas9 gene-edited human HSPCs.
Molecular therapy : the journal of the American Society of Gene Therapy Jan, 2023 | Pubmed ID: 35982622
Choice of template delivery mitigates the genotoxic risk and adverse impact of editing in human hematopoietic stem cells.
Cell stem cell Oct, 2022 | Pubmed ID: 36206730
Case Report: Consistent disease manifestations with a staggered time course in two identical twins affected by adenosine deaminase 2 deficiency.
Frontiers in immunology , 2022 | Pubmed ID: 36248833
Myelomonocytic cells in giant cell arteritis activate trained immunity programs sustaining inflammation and cytokine production.
Rheumatology (Oxford, England) Feb, 2023 | Pubmed ID: 36802235
Protocol to differentiate monolayer human induced pluripotent stem cells into inflammatory responsive astrocytes.
STAR protocols Mar, 2023 | Pubmed ID: 36881505
Longitudinal single-cell profiling of chemotherapy response in acute myeloid leukemia.
Nature communications Mar, 2023 | Pubmed ID: 36890137
JoVEについて
Copyright © 2023 MyJoVE Corporation. All rights reserved